10 Analysts Assess Genmab: What You Need To Know
Portfolio Pulse from Benzinga Insights
Analysts' ratings for Genmab (NASDAQ:GMAB) over the last quarter show a mix of bullish and bearish sentiments. The average 12-month price target is $48.5, with a high of $53.00 and a low of $32.00. Genmab has shown strong financial performance with significant revenue growth and profitability.
June 20, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts' ratings for Genmab (NASDAQ:GMAB) show a mix of bullish and bearish sentiments. The average 12-month price target is $48.5, reflecting a slight increase from the previous target. Genmab has demonstrated strong financial performance with significant revenue growth and profitability.
The majority of analysts maintain a bullish stance on Genmab, with a slight increase in the average price target. The company's strong financial performance, including significant revenue growth and profitability, supports a positive short-term outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100